IRIS
BLANDINI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.728
AS - Asia 4.241
EU - Europa 3.008
SA - Sud America 658
AF - Africa 201
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.853
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.556
CN - Cina 1.533
SG - Singapore 1.058
IE - Irlanda 979
HK - Hong Kong 696
BR - Brasile 493
VN - Vietnam 407
RU - Federazione Russa 397
DE - Germania 333
FI - Finlandia 251
FR - Francia 220
UA - Ucraina 208
IT - Italia 189
GB - Regno Unito 129
ZA - Sudafrica 123
IN - India 103
CA - Canada 94
SE - Svezia 87
BD - Bangladesh 65
JP - Giappone 62
IQ - Iraq 50
AR - Argentina 47
MX - Messico 46
PK - Pakistan 38
CZ - Repubblica Ceca 37
TR - Turchia 36
ID - Indonesia 28
CO - Colombia 25
ES - Italia 25
PL - Polonia 25
EC - Ecuador 24
SA - Arabia Saudita 24
BE - Belgio 23
AT - Austria 20
NL - Olanda 20
LT - Lituania 19
CL - Cile 17
PY - Paraguay 15
VE - Venezuela 15
MA - Marocco 14
MU - Mauritius 14
PH - Filippine 14
UZ - Uzbekistan 14
JO - Giordania 12
AU - Australia 11
EG - Egitto 10
PE - Perù 10
TN - Tunisia 10
AZ - Azerbaigian 9
MY - Malesia 9
AE - Emirati Arabi Uniti 7
DO - Repubblica Dominicana 7
KZ - Kazakistan 7
IL - Israele 6
KE - Kenya 6
KG - Kirghizistan 6
UY - Uruguay 6
CH - Svizzera 5
CR - Costa Rica 5
LB - Libano 5
NP - Nepal 5
SN - Senegal 5
AL - Albania 4
BH - Bahrain 4
BO - Bolivia 4
CY - Cipro 4
ET - Etiopia 4
HR - Croazia 4
KR - Corea 4
PA - Panama 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BN - Brunei Darussalam 3
EE - Estonia 3
EU - Europa 3
GT - Guatemala 3
IS - Islanda 3
JM - Giamaica 3
KH - Cambogia 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
TH - Thailandia 3
BG - Bulgaria 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LY - Libia 2
MR - Mauritania 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
Totale 14.823
Salva come PNG Salva come JPEG
Città #
Chandler 1.008
Dublin 979
San Jose 809
Hong Kong 682
Ashburn 672
Dallas 514
Singapore 494
Beijing 399
Jacksonville 253
Boardman 231
Princeton 190
Lawrence 186
Nanjing 177
Los Angeles 163
Lauterbourg 162
Medford 152
Ho Chi Minh City 143
Wilmington 136
Helsinki 116
New York 112
Hanoi 106
Johannesburg 101
Shanghai 88
Munich 86
Redondo Beach 79
Nanchang 77
Buffalo 71
Shenyang 69
Changsha 62
São Paulo 61
Tokyo 58
Moscow 56
Chicago 52
Council Bluffs 52
Toronto 51
The Dalles 50
Santa Clara 49
Tianjin 47
Hebei 45
Ann Arbor 43
Jiaxing 42
Orem 39
Pavia 37
Brno 32
Milan 32
Chennai 31
Hangzhou 31
Norwalk 31
Brooklyn 30
San Francisco 30
Frankfurt am Main 27
Washington 26
Columbus 25
Turku 25
Brussels 23
London 21
Stockholm 21
Warsaw 21
Da Nang 20
Falkenstein 20
Montreal 20
Nuremberg 20
Denver 19
Seattle 19
Atlanta 18
Baghdad 18
Boston 18
Manchester 18
Guangzhou 17
Mexico City 17
Piscataway 17
Fairfield 16
Lahore 16
Phoenix 16
Düsseldorf 14
New Delhi 14
Rio de Janeiro 14
Woodbridge 14
Haiphong 13
Amsterdam 12
Belo Horizonte 12
Philadelphia 12
Tashkent 12
Amman 11
Des Moines 11
Elk Grove Village 11
Rome 11
Houston 10
Medellín 10
Paris 10
Santiago 10
Vienna 10
Ankara 9
Baku 9
Cairo 9
Can Tho 9
Poplar 9
Riyadh 9
Shijiazhuang 9
Wuhan 9
Totale 9.977
Salva come PNG Salva come JPEG
Nome #
Correlation of LTP and LTD with gene expression in the cerebellar cortex. 175
Alterazioni neurochimiche del sistema nervoso enterico (SNE) in un modello sperimentale di Parkinson 157
Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. 157
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model 150
A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. 146
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 144
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 139
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells 137
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 133
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 131
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 131
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 129
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 127
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats 123
Aging and dementia: markers of the hypothalamus-pituitary-adrenal axis and sympathetic activities in biological fluids 121
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 121
Long-term synaptic plasticity and related gene expression in the cerebellar cortex. 118
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self perpetuating crosstalk? 116
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease 113
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 113
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 111
Stress and Autonomic Nervous System 110
Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury 110
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach 110
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 110
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 106
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 104
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 102
Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease 102
A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation 99
Functional changes of the basal ganglia circuitry in Parkinson's disease. 98
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 98
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 97
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease 97
A 2A receptor antagonism and dyskinesia in parkinson's disease 97
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 97
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 96
Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration 96
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. 94
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease 94
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 94
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 93
Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson׳s disease 93
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 93
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine 93
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 93
Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double‐Blind Placebo Controlled Study 93
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 92
Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients 92
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 92
Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease 92
The role of dopamine in the modulation of gastrointestinal motility in a rat model of Parkinson's disease 91
Mitochondrial Complex i Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease 91
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease 91
Cardiopressor effects of short-term treatment with cabergoline in L-Dopa stable responder parkinsonian patients: Relevance of postprandial hypotension 90
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 90
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 89
Repurposing opportunities for Parkinson’s disease therapies 89
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. 88
Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 87
Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease 87
Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors 87
Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia 87
Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention 86
Nitroglycerin-induced activation of monoaminergic trasmission in the rat 86
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. 86
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 86
Calcium homeostasis is dysregulated in Parkinsonian patients with L-DOPA-induced dyskinesias 86
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease 86
Valutazione delle catecolamine plasmatiche: influenza di fattori ambientali e delle procedure di campionamento 85
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease 85
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 85
Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus 85
Homocysteine and Parkinson's disease: a dangerous liaison? 84
The Involvement of Post-Translational Modifications in Alzheimer's Disease 84
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease 84
Noninvasive neuromodulation in Parkinson's disease: Neuroplasticity implication and therapeutic perspectives 84
Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. 83
From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries 83
Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat 83
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 83
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 83
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: New clues from an old model 82
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. 81
Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. 81
Influence of estrogen modulation on glia activation in a murine model of parkinson's disease 81
Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. 80
Modulation of noradrenergic activity by magnesium salts in panic disorder and neuronal hyperexcitability syndrome 80
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 80
Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells 78
Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells: Possible Relevance for Parkinson's Disease 78
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study 77
Peripheral levels of BDNF and NGF in primary headaches 77
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 77
Characterization of gene expression induced by RTN-1C in human neuroblastoma cells and in mouse brain 76
Facemasks and face recognition: Potential impact on synaptic plasticity 76
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. 75
Intestinal dysmotility and enteric neurochemical changes following nigrostriatal dopaminergic denervation in the rat: relevance to the gastrointestinal dysfunction associated with Parkinson's disease 75
A blood-based marker of mitochondrial DNA damage in Parkinson's disease 74
The Involvement of Post-Translational Modifications in Alzheimer's Disease 74
Totale 9.805
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 0 9
2021/2022816 6 2 34 6 4 16 12 43 51 11 122 509
2022/20232.712 302 199 43 236 218 259 0 165 1.184 9 55 42
2023/2024969 121 146 44 56 92 250 35 56 7 27 57 78
2024/20252.833 121 215 66 80 88 152 145 176 645 142 376 627
2025/20266.025 448 400 648 635 733 213 1.300 337 536 429 218 128
Totale 15.063